Abstract. Peptide hormone relaxin produced in normal and cancer prostate cells can stimulate prostate cancer progression. Suppression of relaxin or relaxin receptor RXFP1 expression inhibited prostate cancer both in vitro and in vivo. RXFP1 is a G protein-coupled receptor with the extracellular low density lipoprotein A (LDL-A) module located at the N-terminus. The LDL-A module exhibits a competitive inhibition effect on the RXFP1 function and might be used to suppress relaxin signaling. In this study, we investigated the effect of LDL-A overexpression on prostate cancer cells. PC3 cells expressing the RXFP1-LDL-A module had a decreased proliferation, soft agar colony formation, adhesion, invasion in vitro, and grew at a slower rate than control cells as tumors in xenograft models in mice. Expression analysis revealed that the RXFP1-LDL-A expression in PC3 cells inhibited Akt phosphorylation and MMP2 activation, and led to the down-regulation of several genes previously implicated in tumorigenesis, such as MMP28, S100P, IGFBP2, MUC1 and S100A4. These results indicate that the inhibition of RXFP1 by peptide based on the LDL-A module of this receptor may be a potential approach for prostate cancer suppression.
Introduction
Relaxin (RLN) is a small peptide hormone of relaxin/insulinlike family (1) . Mouse relaxin shares only 48% identity at the amino acid level with human RLN2, but each is bioactive in both species. While relaxin role in female reproduction and specifically in pregnancy has been studied extensively, its functions in males are more controversial (2, 3) . The expression of the hormone in males has been detected in prostate and in testis, but the concentration of relaxin in peripheral blood is significantly lower than that in females (3) . On the other hand, the expression of relaxin receptor RXFP1, relaxin family peptide receptor 1, is readily detectable in numerous organs (4) . Gene targeting experiments in mice resulted in viable Rln1 and Rxfp1-deficient animals (5-7). Detailed analysis of their phenotype revealed an involvement of this peptide in extracellular matrix remodeling; a fibrosis development was described in various Rln1-or Rxfp1-deficient organs (8) . The role of relaxin in regulation of angiogenesis and vasodilation was linked to the induction of vascular endothelial growth factor, up-regulation of nitric oxide synthase, matrix metalloproteases and other factors (9) . Modulations of relaxin signaling affect cell proliferation, apoptosis, cell migration, invasiveness, adhesion and other cell characteristics important in the context of normal development as well as in oncogenic transformation. In the last several years the potential role of relaxin in prostate cancer tumorigenesis was under investigation (10) (11) (12) (13) (14) (15) (16) (17) . Relaxin and RXFP1 are well-expressed in normal epithelial prostate cells as well as in prostate cancer cells. We have shown that an increased relaxin expression in tumor patient samples correlated with aggressive metastatic disease and shorter overall survival (13) . It was reported that the relaxin expression became up-regulated during prostate cancer progression to androgen independence and was negatively regulated by androgens (12) . The experiments with androgen receptor positive and negative LNCaP and PC3 prostate adenocarcinoma cells revealed the stimulating effects of relaxin on cell proliferation, migration, and adhesion in vitro (13) . Similarly, in the LNCaP/PC3 xenograft experiments the overexpression of relaxin in cancer cells increased tumor growth, vascularization and metastasis rates (11, 16) , whereas an overexpression of relaxin homolog with antagonistic properties decreased tumor growth (14) . We have shown that systemic transgenic overexpression of relaxin in mice decreased survival of TRAMP (transgenic adenocarcinoma of mouse prostate) mutant males (13) . Treatment of prostate cancer xenografts with chitosan nanoparticles containing siRNA targeting RXFP1 decreased tumor growth and number of metastases (17) .
As other G protein-coupled receptors RXFP1 is expressed on the cell surface membrane and hence is an attractive target for therapeutic intervention. Stimulation of RXFP1 causes an activation of cAMP through Gs/Gi proteins and protein kinase A in some, but not all cells (18) . An involvement of tyrosine kinases, protein kinase C zeta, PI3 kinase and other molecules in relaxin receptor signaling was also demonstrated (18) . The extracellular part of the relaxin receptor contains 10 leucine-rich repeats and a low-density lipoprotein module A (LDL-A) at the N-terminus of the protein (4) . The mutations in LDL-A abolish the receptor signaling, but not the hormone binding (18) . Treatment of the RXFP1 transfected cells with a peptide designed based on LDL-A module suppressed relaxininduced cAMP activation, suggesting the antagonistic behavior (19) . Taking into account the effect of relaxin signaling on tumor progression we analyzed the effect of RXFP1-LDL-A expression on cancer cells in vitro and in xenograft experiments in mice. The results indicated that the stable transfection of PC3 adenocarcinoma cells with the RXFP1-LDL-A expression vector suppressed tumorigenic properties of cancer cells with a corresponding decrease in the expression of several genes involved in prostate tumor progression.
Material and methods
Cell cultures. The PC3 cells, originally purchased from American Type Culture Collection, Inc. (Manassas, VA) were maintained in 1:1 mixture of Ham's Nutrient mixture F12 and DMEM (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum, 100 units penicillin/ml and 100 µg streptomycin/ml (Invitrogen).
Production of RXFP1-LDL-A transfected PC3 cells. FLAGtagged human RXFP1-LDL-A mammalian expression construct FLAG-RXFP1-LDL-A/pcDNA3.1/Zeo was generated by PCR using human RXFP1-pcDNA3.1/Zeo plasmid (4) with a forward T7 primer and a reverse primer (5'-GGG GGC CCT TAC TCT CCA CAG TTG TCC TCA TC-3') containing an ApaI site. The resultant product was cloned into BamH1/ApaI sites of pcDNA3.1/Zeo and fully sequenced. The FLAG-RXFP1-LDL-A/pcDNA3.1/Zeo and vector pcDNA3.1/ Zeo plasmids were used to obtain stable transfected PC3 cell lines using the Nucleofector Kit V with Nucleofector device (Lonza Group Ltd., Gaithersburg, MD). Transfected cells were selected with 500 ng/ml Zeocin (Invitrogen, determined by the kill curve assay). Individual resistant clones were picked 3 weeks later and expanded into the cell lines.
Cell proliferation assay. Cell proliferation was estimated using the CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega, Madison, WI) as previously described (13) . Eight replicate per cell lines were assayed, and data averaged from three separate experiments are presented.
Adhesion assay. The adhesion of the stable transfected cells and the parental PC3 cells to type I collagen was determined as previously described (13) . All measurements were repeated six times/group in three independent experiments.
Colony formation and soft agar colony formation assay. For colony formation assay, 5000 cells were plated in 6-well plates. The medium was changed every 3 days. On the 12th day, the plates were stained with 1% crystal violet, and the colonies were quantified. Colony formation in soft agar was performed as previously described (13) . Briefly, a suspension of 5000 cells/ml cells was prepared in 0.35% agar diluted in growth medium and plated on a 3.5% agar foundation in 6-well culture plate. After 14 days culture, cells were stained with 2 mg/ml of p-iodonitrotetrazolium violet (Sigma, St. Louis, MO) at 37˚C for 24 h. Colonies were counted under dissecting microscope. Experiments were repeated three times.
Matrigel invasion assay. BD BioCoat Matrigel invasion
Chambers with Matrigel inserts with 8 µm pores (BD Biosciences, Bedford, MA) were used for cell invasion assay as previously described (13) . All experiments were performed three times; each point was repeated in triplicate.
Western blot analysis. Specific RXFP1 and negative control siRNA were supplied by Qiagen (Valencia, CA). The siRNA sequence used for RXFP1 gene silencing (siRXFP1) was GGAUGUCAAGUGCUCCCUUtt (sense strand) (13, 17) . Negative control siRNA (siNC) with no significant sequence similarity to human gene sequences was used as control. The PC3 cells were transfected with siRXFP1 and siNC (5 µg each) using Nucleofector device as previously described (17) . Transfected cells were harvested after 72 h, the protein was extracted from the total cell lysate for Western blot experiments. In parallel experiment, the protein was extracted from the FLAG-RXFP1-LDL-A and pcDNA3.1/Zeo vector control PC3 cells. The extracted proteins (30 µg) were subjected to Western blot analysis using phospho-Akt (Thr308) or total Akt antibodies (1:1000, Cell Signaling Technology, Danvers, MA). A goat polyclonal anti-β-actin antibody (Santa Cruz Biotechnology, Santa Cruz, CA) at 1:1000 was used as an internal control.
Zymography. Gelatinolytic zymography was used to detect the activity of MMP-2 and MMP-9 in conditioned media of FLAG-RXFP1-LDL-A and vector control stable transfected PC3 cells. Briefly, cells were incubated in serum-free medium for 72 h in 6-well plates. The conditioned media were collected by centrifuging at 4˚C at 13200 rpm for 30 min. Samples of 20 µg were mixed with non-denaturing loading buffer and separated in 10% SDS-polyacrylamide gels containing 1 mg/ml gelatin. After electrophoresis, gels were washed with 2.5% Triton X-100 for 1 h three times to remove SDS before incubation for 24 h at 37˚C in developing buffer (50 mM Tris-HCl pH 8.0, 5 mM CaCl 2 , 5 µM ZnCl 2 and 0.02% NaN 3 ). Gels were fixed and stained with 50% methanol and 10% acetic acid containing 0.3% w/v Coomassie Blue. Experiments were performed in duplicate three times.
RNA isolation and RT-PCR.
Total RNA was isolated from cells using the RNeasy kit (Qiagen, MD, USA) and digested with the DNA-free™ DNase Treatment and Removal Reagents (Ambion, Austin, TX), according to the manufacturer's protocol. cDNA was synthesized using an oligo(dT) primer and RETROscript Kit (Ambion). The FLAG-RXFP1-LDL-A expression was analyzed by RT-PCR with primers PRLsignalPep forward (5'-ATG GAC AGC AAA GGT TCG TC-3') and RXFP1-LDL-A reverse (5'-TCT CCA CAG TTG TCC TCA TCG G-3'). RT-PCR with primers for β-actin gene, β-actin forward, 5'-CCAAGGCCAACCGCGAGAAGATGAC-3', and β-actin reverse, 5'-AGGGTACATGGTGGTGCCGCCAGAC-3', was used to assess the quality of cDNA pools. Real-time quantitative RT-PCR (QRT-PCR) was performed with a qPCR SYBR Green real-time protocol on the IQ5 iCycler (Bio-Rad, Hercules, CA). Primers for different genes are available upon the request. All data were normalized to GAPDH gene expression. Each point was done at least in triplicate and the average and standard errors were calculated.
Xenograft studies. All experiments were conducted using the standards for humane care in accordance with the NIH Guide for the Care and Use of Laboratory Animals and approved by the Baylor College of Medicine Institutional Committee. A total of 10 7 RXFP1-LDL-A stable transfected PC3 cells (LDL5) or vector control cells (V14) in 200 µl of a 1:1 mixture of DMEM/F12 and Matrigel (BD Biosciences, Bedford, MA) were injected subcutaneously into two abdominal flanks of 6-week male nude mice (12 per group) obtained from NCI Animal Production Program. The tumors were measured twice a week using a digital slide caliper and the tumor volume in cubic millimeters was calculated by the following formula: volume = width 2 x length/2. After eight weeks mice were sacrificed; tumors were dissected, lung, liver, kidneys, brain and lymph nodes were analyzed for the presence of metastases.
Immunohistochemistry. The tumor sections were prepared using standard protocol. Tumor cell proliferation was evaluated by immunohischemistry (IHC) using anti-Ki67 (1:100 dilution; Abcam, Cambridge, MA). Images were taken with a Nikon-TMS inverted microscope equipped with Olympus DP70 digital imaging system. Ki67 staining was scored by the percentage of positive tumor cells in eight random fields per section at x400 magnification in each tumor section.
Statistical analysis. Student's t-test was employed. All experiments were performed at least in triplicates and were expressed as mean ± standard error, with P<0.05 considered as statistically significant. Analysis of the xenograft growth was performed by two-way ANOVA using GraphPad Prism Software (La Jolla, CA).
Results
To determine the effect of LDL-A module of relaxin receptor overexpression on prostate cancer progression, we generated stable transfectants of PC3 cells that express RXFP1-LDL-A. PC3 cells were transfected with a human RXFP1-LDL-A mammalian expression construct FLAG-RXFP1-LDL-A/ pcDNA3.1zeo or pcDNA3.1zeo vector as a control (Fig. 1A) . Presence of the plasmid DNA was confirmed by PCR with vector-specific primers (data not shown). Several individual clones were obtained for each group. The RXFP1-LDL-A mRNA expression was evaluated in 5 clones using RT-PCR with primers specific for PRL-SP and LDL-A as shown in Fig. 1B . The following clones from each group were used in further studies: control, V14; LDL-A, LDL5 or LDL8.
Effect of stable transfection of RXFP1-LDL-A on PC3 cell tumorigenic properties in vitro.
To analyze the effect of RXFP1-LDL-A expression on cell growth, the parental PC3 cells, RXFP1-LDL-A stable transfectant LDL5 and LDL8 cell lines, and vector control V14 cells were used. Cell proliferation was determined at different time points. As shown in Fig. 2A , both LDL5 and LDL8 cells exhibited decreased proliferation compared to control V14 cells or parental PC3 cells. Adhesion assay showed that the LDL-A overexpression in LDL5 and LDL8 cells also inhibited cell adhesion to type I collagen (Fig. 2B) . The transfected cells were also examined for colony formation and anchorage-independent growth in a soft agar medium. The results showed that LDL5 and LDL8 cells exhibited a lower colony formation capacity on solid surface of culture dishes compared to the vector control or parental PC3 cells (Fig. 3A) . All cell lines exhibited anchorage-independent growth in soft agar. As shown in Fig. 3B, LDL5 and LDL8 cells formed fewer colonies in soft agar compared to the V14 and parental PC3 cells (P<0.001) suggesting an effect of RXFP1-LDL-A expression and a decreased survival/growth advantage in anchorage-independent condition. We tested whether RXFP1-LDL-A affected prostate cancer cell invasiveness in an in vitro Matrigel invasion assay. About two to three times fewer RXFP1-LDL-A expressing LDL5 and LDL8 cells traversed the Matrigel than did control V14 or PC3 cells (Fig. 4A) . Gelatin zymography showed that the MMP2 activity in LDL5 cells was significantly lower compared to the control V14 cells (Fig. 4B) , suggesting that the modulation of MMP2 activity might be responsible for the decreased invasiveness in LDL-A overexpressing cells.
Previously relaxin-induced modulation of Akt protein kinase B (PKB) phosphorylation was shown for LNCaP cells (15) . The activity of Akt is implicated in mediating a variety of biological responses including cell growth, proliferation and survival (20) . To determine whether RXFP1-LDL-A expression impact Akt activation, we assessed the levels of phospho-Akt in LDL5 and V14 cells as well as in PC3 cells transfected with siRNA targeting RXFP1 expression. The data in Fig. 4C shows that the expression of RXFP1-LDL-A was able to inhibit the Akt phosphorylation. The same effect was observed in PC3 cells with a knock-down of RXFP1 expression by siRNA (Fig. 4D) .
The QRT-PCR with RNA isolated from control (V14) and RXFP1-LDL-A transfected (LDL5) cell lines was performed for several genes previously identified as the potential targets (17, 21, 22) of relaxin signaling (Fig. 5) . All tested genes showed a significant down-regulation.
RXFP1-LDL-A expression suppresses PC3 tumor growth in xenografts.
Since RXFP1-LDL-A expression inhibited several tumorigenic properties of the cancer cells in vitro, we investigated whether RXFP1-LDL-A would alter the growth of the xenografts derived from PC3 cells in nude mice. The LDL5 and V14 cells were inoculated subcutaneously both into the left and right flanks of the intact 2-month old nude males. The tumor take in the groups did not differ [10/12 (83.33%) in both groups]. The tumor growth was monitored for the next eight weeks. The LDL5 tumors grew slower than the control V14 tumors (P<0.001, two-way ANOVA). At day 36 post inoculation the difference in the tumor volume became statistically significant (Fig. 6A) . At the end of the experiment the difference between two groups remained, however, the average tumor volumes became somewhat closer. As shown in Fig. 6B , the primary tumor weight was decreased 66% in LDL5 group comparing to control, but the difference was not statistically significant (P=0.1387, Student's t-test). It is possible that a long incubation period led to a gradual loss of transfected protein expression in LDL5 cells.
Histopathological examinations of the tumors revealed no apparent differences among two groups of mice studied. Metastases were not detected in the organs studied except one case of lymph node tumor growth in V14 group. IHC with Ki67 marker was performed to evaluate tumor cell proliferation in the RXFP1-LDL-A expressing LDL5 and vector control V14 tumors. The lower expression level of Ki67 in LDL5 xenografts compared to the vector control V14 group was statistically significant (Fig. 6C) .
Discussion
The role of relaxin has been recently demonstrated in breast, endometrial, thyroid, and prostate cancer progression (23) . As other growth factors expressed in cancer cells relaxin acts as an autocrine/paracrine stimulus increasing proliferation, invasiveness, and cell adhesion. Additionally, it was shown that relaxin increases vascularization and angiogenesis either directly or indirectly through the stimulation of VEGF or other cell signals. An increased relaxin expression in cancer samples was associated with the more aggressive disease and a decline in survival of the patients (13, 24) . Several attempts have been made to evaluate the effects of relaxin and relaxin receptor suppression as a potential therapeutic strategy. Such experiments included the analysis of tumor growth using prostate cancer cells stably transfected with relaxin peptide homolog with antagonistic properties (14) and nanoparticle delivery of siRNA targeting RXFP1 (17) . Here, we used prostate cancer PC3 cells overexpressing LDL-A module of the relaxin receptor. We have determined that an overexpression of this peptide suppressed growth, adhesion, colony formation, invasiveness of prostate cells in vitro, and xenograft tumor growth in vivo.
The RXFP1 receptor belongs to the leucine rich repeat (LRR) G protein-coupled receptor family (2) . The unique feature of this receptor and the related RXFP2 receptor of insulin-like 3 peptide is the presence of N-terminus low-density lipoprotein receptor type A module. Using various mutant and chimeric receptors it was shown that the binding of relaxin by LRR is not sufficient for activation of the receptor (18) . No cAMP activation occurred in receptors lacking LDL-A or in mutants with distorted structure of this module (18) . As a result, a three step model of relaxin receptor activation was proposed involving relaxin binding by LRR, its interaction with the extracellular loops, and the LDL-A directed receptor activation (19) . Significantly, the soluble RXFP1-LDL-A peptide was able to suppress cAMP activation in cells with transfected RXFP1 (4) . Injections of the recombinant peptide corresponding to the whole extracellular domain of RXFP1 had a suppressive effect on nipple development and delayed parturition in mice (25) . Multiple splice variants of RXFP1 gene, some of them containing LDL-A module have been detected in numerous tissues (19, 26, 27) . It was suggested that expression of such peptides may be responsible for a modulation of relaxin signaling.
The PC3 cells express relaxin receptor RXFP1, however, the stimulation with hormone does not cause an appreciable increase in cAMP as in receptor transfected HEK293 cells or in monocytic leukemia THP1 cells. Thus, we evaluated the effect of LDL-A transfection on the known responses of these cells to relaxin stimulation. It has been shown previously that the addition of relaxin could cause an increase in invasiveness, migration, cell adhesion, colony formation, as well as an increase in cell proliferation (10) (11) (12) (13) (15) (16) (17) . Suppression of relaxin signaling using siRNA targeting hormone or receptor mRNAs had an opposite effect (13, 17) . We showed here that the transfection with RXFP1-LDL-A indeed affected all of these cellular functions in vitro, and significantly suppressed tumor growth in vivo.
Several potential cell signaling mechanisms controlled by relaxin have been described. In androgen receptor positive LNCaP cells relaxin activates AR through an activation of β-catenin, which is accompanied by phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) activation and phosphorylation/degradation of glycogen synthase kinase-3β (GSK-3β) (15) . An activation of Wnt/β-catenin pathway has been also demonstrated in LNCaP cells overexpressing relaxin, through the activation of Protocadherin Y (PCDHY) and stabilization/nuclear translocation of β-catenin (16) . Both relaxin and PCDHY are negatively regulated by androgens (12, 16) . We demonstrated here that the siRNA suppression of RXFP1 and the LDL-A expression in PC3 cells resulted in significant decrease of Akt phosphorylation, suggesting a common relaxin/β-catenin/Akt activation pathway in both PC3 and LNCaP prostate cell lines.
Previously we have performed a whole genome expression analysis of PC3 cells transfected with siRNA against RXFP1 (17) . Remarkably, several missregulated genes were common between two experiments. In current experiment, the LDL-A was expressed in a stable manner, and thus, had a long-term effect on cancer cells. In siRNA knockdown treatment the effect of an acute down-regulation of relaxin signaling in PC3 cells was evaluated. The well-established modulators of prostate cancer progression such as MUC1, IGFBP2, S100A4, previously identified as the targets of relaxin signaling were also missregulated in RXFP1-LDL-A expressing PC3 cells (17, 28) . Although we cannot exclude some non-specific effects of RXFP1-LDL-A stable expression, the data indicate that relaxin signaling might be affected in transfected cells.
In summary, we have shown that the overexpression of RXFP1-LDL-A domain in prostate adenocarcinoma PC3 cells reduced their tumorigenic properties and thus identify relaxin signaling as a potential therapeutic target for cancer treatment.
